Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | GAA | P10253 | 1/20 | 0.80 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.67 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 5/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 8/20 | 0.60 |
| ▸ | HTR2A | P28223 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR1E | P28566 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626635 | 0.89 | MAPT (1.00) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL646273 | 0.89 | MAPT (1.00) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL22800099 | 0.89 | MAPT (1.00) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL31289353 | 0.88 | MAPT (0.97) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL31289351 | 0.88 | MAPT (0.97) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL31289358 | 0.86 | MAPT (0.95) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL29373710 | 0.85 | HTR2B (0.74) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL764888 | 0.84 | HTR2B (0.72) | HTR2BMAPTALDH1A1MAPKAPK2MAPKAPK5 | |
| SCHEMBL14043228 | 0.83 | HTR7 (0.71) | HTR2BMAPTALDH1A1KDM4EPSMD14 | |
| SCHEMBL6240399 | 0.82 | HTR7 (0.70) | HTR2BMAPTALDH1A1KDM4EPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| US-5580878-A | TREATING SLEEP DISORDERS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | claimed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| US-5403851-A | Central nervous system and psychological disorders | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| US-5314908-A | Compounds useful as antiproliferative agents | WHITBY RESEARCH, INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0549916-A2 | Compounds useful as antiproliferative agents | WHITBY RESEARCH, Inc. (US) | 1993-07-07 | — | — | EP | disclosed |
| US-5206377-A | Compounds useful as antiproliferative agents | WHITBY RESEARCH, INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0281242-A1 | Beta-alkylmelatonins | ELI LILLY AND COMPANY (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR2B 9/4885MAPT 3403/4885ALDH1A1 3084/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2B 28/4885MAPT 1422/4885ALDH1A1 1406/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR2B 9/4885MAPT 635/4885ALDH1A1 1691/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR2B 5/4885MAPT 2165/4885ALDH1A1 3289/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR2B 14/4885MAPT 1912/4885ALDH1A1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.